Literature DB >> 27981569

Genetic advances uncover mechanisms of chemotherapy-induced peripheral neuropathy.

K C Chua1, D L Kroetz1.   

Abstract

Chemotherapy-induced peripheral neuropathy (CIPN) is a common dose-limiting toxicity experienced in 30-40% of patients undergoing treatment with various chemotherapeutics, including taxanes, vinca alkaloids, epothilones, proteasome inhibitors, and thalidomide. Importantly, CIPN significantly affects a patient's quality of life. Recent genetic association studies are enhancing our understanding of CIPN pathophysiology and serve as a foundation for identification of genetic biomarkers to predict toxicity risk and for the development of novel strategies for prevention and treatment.
© 2016 American Society for Clinical Pharmacology and Therapeutics.

Entities:  

Mesh：

Substances：

Year:  2017        PMID： 27981569      PMCID： PMC5359049          DOI： 10.1002/cpt.590

Source DB:  PubMed          Journal:  Clin Pharmacol Ther        ISSN： 0009-9236            Impact factor:   6.875


  5 in total

1.  A genome-wide association study identifies novel loci for paclitaxel-induced sensory peripheral neuropathy in CALGB 40101.

Authors:  R Michael Baldwin; Kouros Owzar; Hitoshi Zembutsu; Aparna Chhibber; Michiaki Kubo; Chen Jiang; Dorothy Watson; Rachel J Eclov; Joel Mefford; Howard L McLeod; Paula N Friedman; Clifford A Hudis; Eric P Winer; Eric M Jorgenson; John S Witte; Lawrence N Shulman; Yusuke Nakamura; Mark J Ratain; Deanna L Kroetz
Journal:  Clin Cancer Res       Date:  2012-07-27       Impact factor: 12.531

2.  Oxaliplatin-induced neurotoxicity is dependent on the organic cation transporter OCT2.

Authors:  Jason A Sprowl; Giuliano Ciarimboli; Cynthia S Lancaster; Hugh Giovinazzo; Alice A Gibson; Guoqing Du; Laura J Janke; Guido Cavaletti; Anthony F Shields; Alex Sparreboom
Journal:  Proc Natl Acad Sci U S A       Date:  2013-06-17       Impact factor: 11.205

Review 3.  Prevention and management of chemotherapy-induced peripheral neuropathy in survivors of adult cancers: American Society of Clinical Oncology clinical practice guideline.

Authors:  Dawn L Hershman; Christina Lacchetti; Robert H Dworkin; Ellen M Lavoie Smith; Jonathan Bleeker; Guido Cavaletti; Cynthia Chauhan; Patrick Gavin; Antoinette Lavino; Maryam B Lustberg; Judith Paice; Bryan Schneider; Mary Lou Smith; Tom Smith; Shelby Terstriep; Nina Wagner-Johnston; Kate Bak; Charles L Loprinzi
Journal:  J Clin Oncol       Date:  2014-04-14       Impact factor: 44.544

Review 4.  Chemotherapy-induced peripheral neuropathy: Current status and progress.

Authors:  Jamie R Brewer; Gladys Morrison; M Eileen Dolan; Gini F Fleming
Journal:  Gynecol Oncol       Date:  2015-11-07       Impact factor: 5.482

5.  Modeling chemotherapeutic neurotoxicity with human induced pluripotent stem cell-derived neuronal cells.

Authors:  Heather E Wheeler; Claudia Wing; Shannon M Delaney; Masaaki Komatsu; M Eileen Dolan
Journal:  PLoS One       Date:  2015-02-17       Impact factor: 3.240
  5 in total
  9 in total

1.  Genome-wide association study of aromatase inhibitor discontinuation due to musculoskeletal symptoms.

Authors:  Daniel L Hertz; Julie A Douglas; Robert M Miller; Kelley M Kidwell; Christina L Gersch; Zeruesenay Desta; Anna Maria Storniolo; Vered Stearns; Todd C Skaar; Daniel F Hayes; N Lynn Henry; James M Rae
Journal:  Support Care Cancer       Date:  2022-07-01       Impact factor: 3.359

2.  Genetic variants predictive of chemotherapy-induced peripheral neuropathy symptoms in gynecologic cancer survivors.

Authors:  Lauren Thomaier; Burcu F Darst; Patricia Jewett; Cody Hoffmann; Katherine Brown; Aditi Makaram; Anne Blaes; Peter Argenta; Deanna Teoh; Rachel I Vogel
Journal:  Gynecol Oncol       Date:  2021-10-18       Impact factor: 5.304

Review 3.  Exploring pharmacogenetics of paclitaxel- and docetaxel-induced peripheral neuropathy by evaluating the direct pharmacogenetic-pharmacokinetic and pharmacokinetic-neuropathy relationships.

Authors:  Daniel L Hertz
Journal:  Expert Opin Drug Metab Toxicol       Date:  2021-01-06       Impact factor: 4.481

Review 4.  Mechanisms of Chemotherapy-Induced Peripheral Neuropathy.

Authors:  Renata Zajączkowska; Magdalena Kocot-Kępska; Wojciech Leppert; Anna Wrzosek; Joanna Mika; Jerzy Wordliczek
Journal:  Int J Mol Sci       Date:  2019-03-22       Impact factor: 6.208

5.  RgIA4 Accelerates Recovery from Paclitaxel-Induced Neuropathic Pain in Rats.

Authors:  Peter N Huynh; Denise Giuvelis; Sean Christensen; Kerry L Tucker; J Michael McIntosh
Journal:  Mar Drugs       Date:  2019-12-21       Impact factor: 5.118

Review 6.  Peripheral Neuropathy under Oncologic Therapies: A Literature Review on Pathogenetic Mechanisms.

Authors:  Mariarita Laforgia; Carmelo Laface; Concetta Calabrò; Simona Ferraiuolo; Valentina Ungaro; Domenico Tricarico; Cosmo Damiano Gadaleta; Patrizia Nardulli; Girolamo Ranieri
Journal:  Int J Mol Sci       Date:  2021-02-17       Impact factor: 6.208

Review 7.  Cellular Pathogenesis of Chemotherapy-Induced Peripheral Neuropathy: Insights From Drosophila and Human-Engineered Skin Models.

Authors:  Grace Ji-Eun Shin; Hasan Erbil Abaci; Madison Christine Smith
Journal:  Front Pain Res (Lausanne)       Date:  2022-07-08

8.  Genetic polymorphism of pleiotrophin is associated with pain experience in Japanese adults: Case-control study.

Authors:  Kosuke Saita; Masahiko Sumitani; Daisuke Nishizawa; Takashi Tamura; Kazutaka Ikeda; Kenji Wakai; Yoshika Sudo; Hiroaki Abe; Jun Otonari; Hiroaki Ikezaki; Kenji Takeuchi; Asahi Hishida; Keitaro Tanaka; Chisato Shimanoe; Toshiro Takezaki; Rie Ibusuki; Isao Oze; Hidemi Ito; Etsuko Ozaki; Daisuke Matsui; Yohko Nakamura; Miho Kusakabe; Sadao Suzuki; Hiroko Nakagawa-Senda; Kokichi Arisawa; Sakurako Katsuura-Kamano; Kiyonori Kuriki; Yoshikuni Kita; Yasuyuki Nakamura; Yukihide Momozawa; Kanji Uchida
Journal:  Medicine (Baltimore)       Date:  2022-09-16       Impact factor: 1.817

9.  Sexual dimorphic impacts of systemic vincristine on lower urinary tract function.

Authors:  Nao Iguchi; Sarah L Hecht; Dexiang Gao; Duncan T Wilcox; Anna P Malykhina; Nicholas G Cost
Journal:  Sci Rep       Date:  2022-03-24       Impact factor: 4.379
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.